Effect of quinidine and bretylium on defibrillation energy requirements☆
References (18)
- et al.
Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs
Am Heart J
(1979) - et al.
The effects of cardiovascular drugs on the defibrillation threshold and the pathological effects on the heart using an automatic implantable defibrillator
Ann Thorac Surg
(1983) - et al.
The effect of quinidine on electrical energy required for ventricular defibrillation
Am Heart J
(1966) - et al.
Quinidine toxicity and its treatment. An experimental study
Am Heart J
(1963) - et al.
Kinetics of antifibrillatory effects of bretylium: Correlation with myocardial drug concentrations
Am J Cardiol
(1980) - et al.
Comparison of bretylium tosylate and lidocaine in management of out of hospital ventricular fibrillation: A randomized clinical trial
Am J Cardiol
(1981) Recent advances in cardiopulmonary resuscitation and defibrillation
Curr Probl Cardiol
(1983)- et al.
Effect of ischemia, hypertrophy, hypoxia, acidosis, and alkalosis on canine defibrillation
Am J Physiol
(1983) - et al.
Electrical defibrillation
(1980)
Cited by (47)
Testing and programming of implantable defibrillator functions at implantation
2007, Clinical Cardiac Pacing, Defibrillation, and Resynchronization TherapyTesting and programming of implantable defibrillator functions at implantation
2006, Clinical Cardiac Pacing, Defibrillation and Resynchronization TherapyEffects of antiarrhythmic medication on implantable cardioverter- defibrillator function
2000, American Journal of CardiologyCitation Excerpt :As opposed to the class I agents, class III agents (other than amiodarone) appear either to have no effect or to lower the DFT. In canine preparations, bretylium had no effect,12,16 while N-acetyl procainamide (NAPA), a metabolite of procainamide with pure class III effects, significantly reduced the DFT.13 Sotalol was associated with a reduction in the E50 (energy that resulted in cardioversion 50% of the time) by 16%.22
Interactions between implantable cardioverter-defibrillators and class III agents
1998, American Journal of CardiologyDrugs in modern resuscitation
1997, British Journal of Anaesthesia
- ☆
This research was supported in part by a gift from Intec Systems, Inc., Pittsburgh, Pa.
- 1
Dr. Dorian was supported by a fellowship from the Medical Research Council of Canada.
- 2
Mr. Fain is an American Heart Association Medical Student Research Fellow.
- ∗
Current address: Service de Cardiologie Hospital A. Beclere, 157 rue de la Porte de Trivaux, 92141, Clamart, France.
- 3
Dr. Davy was supported by a grant from the Fondation pour La Recherche Medicale.
- ∗∗
Current address: Cardiovascular Medicine, 770 Welch Rd., Suite 100, Palo Alto CA 94304.